8-KMaterial AgreementsFinancial EventsExhibits & Filings

BIOGEN INC. 8-K Report, Material Agreement (Sep 1, 2015)

Filed September 1, 2015For Securities:BIIB

Summary

Biogen Inc. (BIIB) announced on September 1, 2015, the entry into a new $1.0 billion five-year unsecured, revolving credit facility with Bank of America, N.A., as administrative agent. This facility, established on August 28, 2015, provides significant financial flexibility for the company, with borrowings available for working capital, capital expenditures, acquisitions, and other general corporate purposes. Importantly, Biogen had not drawn down any proceeds from this facility as of its closing date, indicating a proactive approach to securing liquidity. The terms of the credit facility include interest rates tied to either LIBOR or a Base Rate, with margins that vary based on Biogen's debt ratings. A key financial covenant requires the company to maintain a consolidated leverage ratio of no more than 3.5 to 1.0.

Key Highlights

  • 1Biogen entered into a $1.0 billion, five-year unsecured revolving credit facility.
  • 2The facility provides access to funds for working capital, capital expenditures, acquisitions, and other corporate needs.
  • 3No funds were drawn from the credit facility at the time of its closing, demonstrating ample existing liquidity.
  • 4Interest rates are based on LIBOR or a Base Rate, with margins dependent on Biogen's credit ratings.
  • 5The credit facility includes customary covenants, representations, and events of default.
  • 6A key financial covenant requires maintaining a maximum consolidated leverage ratio of 3.5 to 1.0.
  • 7The facility offers flexibility with permitted voluntary prepayments without penalty.

Frequently Asked Questions

The $1.0 billion revolving credit facility is intended to provide Biogen with financial flexibility for various corporate purposes, including working capital needs, capital expenditures, strategic acquisitions, and other general corporate objectives.

No, as of the closing date of the Credit Agreement on August 28, 2015, Biogen had not drawn down any proceeds from this revolving credit facility, indicating strong current liquidity.

Borrowings will accrue interest at rates based on either the London Interbank Offered Rate (LIBOR) or a Base Rate, plus an applicable margin that adjusts based on Biogen's credit ratings. The facility matures in five years from the closing date, with principal repayment due at maturity. Voluntary prepayments are permitted without premium or penalty.

Yes, the Credit Agreement includes customary covenants and events of default. A significant financial covenant requires Biogen to maintain a maximum consolidated leverage ratio of 3.5 to 1.0, measured quarterly.